Detalles de la búsqueda
1.
A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Value Health
; 24(11): 1651-1659, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34711366
2.
Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
Future Oncol
; 17(24): 3163-3174, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34098737
3.
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England.
Pharmacoecon Open
; 5(2): 251-260, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33332018
4.
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
Pharmacoeconomics
; 39(3): 345-356, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428174
5.
A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
Pharmacoeconomics
; 38(4): 385-395, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31848900
6.
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology.
Clinicoecon Outcomes Res
; 11: 309-324, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31118714
7.
Early Access to Medicines Scheme: real-world data collection.
Drug Discov Today
; 24(12): 2231-2233, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31228615
Resultados
1 -
7
de 7
1
Próxima >
>>